Advertisement


Dung T. Le, MD, on Noncolorectal GI Cancers: Results From a Phase II Study of Pembrolizumab

2016 Gastrointestinal Cancers Symposium

Advertisement

Dung T. Le, MD, from Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, reports findings on this agent, which showed promising activity in patients with previously treated progressive, advanced cancer (Abstract 195).



Related Videos

Gastroesophageal Cancer

Dung T. Le, MD, on Gastric or Gastroesophageal Junction Cancer: Results From the CheckMate-032 Trial

Dung T. Le, MD, from Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, discusses study findings on the safety and activity of nivolumab monotherapy in advanced an...

Colorectal Cancer

Daniel G. Haller, MD, on Colon and Rectal Cancers: A Global Overview

Daniel G. Haller, MD, of the Abramson Cancer Center, discusses emerging global approaches to these diseases, emphasizing the studies that allow physicians to individualize treatmen...

Gastroesophageal Cancer

Simron Singh, MD, on Neuroendocrine Tumors of the GI Tract: Results from the RADIANT-4 Trial

Simron Singh, MD, of the Toronto Sunnybrook Cancer Centre, discusses an analysis of data from this phase III study on the efficacy and safety of everolimus in advanced, progressive...

Colorectal Cancer

Heinz-Josef Lenz, MD, on Metastatic Colorectal Cancer: Results of the MAVERICC Study

Heinz-Josef Lenz, MD, of the USC Norris Comprehensive Cancer Center, discusses the findings of this phase II study of mFOLFOX6/bevacizumab vs FOLFIRI/bevacizumab with biomarker str...

Pancreatic Cancer

James L. Abbruzzese, MD, on Pancreatic Cancer: Expert Perspective

James L. Abbruzzese, MD, of Duke University, discusses the international outlook on patterns of care and their impact on outcomes.

Advertisement

Advertisement



Advertisement